Sadioglu Cagdas Oznur, Gokcen Neslihan, Yazici Ayten, Cefle Ayse
Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kocaeli University Hospital, Kocaeli, Turkey.
Rheumatol Int. 2024 Dec 28;45(1):10. doi: 10.1007/s00296-024-05763-6.
Hematological markers such as the neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), and platelet-lymphocyte ratio (PLR) are reliable indicators of inflammation. This study aims to investigate the potential role of these markers in assessing disease activity and treatment response in biologic-naive Ankylosing Spondylitis (AS) patients following the initiation of biological agents.
We designed this study as a retrospective cohort study with data obtained from a single center. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and The Bath Ankylosing Spondylitis Functional Index (BASFI) were used to evaluate disease activity and functional status of AS patients. Laboratory results at baseline, 3rd, 6th, and 12th months were documented. We calculated hematologic inflammatory markers for each visit. Mean platelet volume (MPV) and red cell distribution width (RDW) were also noted.
54 biologic-naive patients with AS were included in this study. These inflammatory markers, except RDW, decreased over time. BASDAI, BASFI, CRP and ESR were significantly lower at 3rd, 6th, and 12th months compared to baseline values (all p < 0.001). Furthermore, NLR, PLR, and MLR showed a statistically significant decrease at 3rd, 6th, and 12th months compared to baseline values (all p < 0.001). However, when comparing the values at the 3rd, 6th, and 12th months, no statistically significant differences were observed. We also found no correlation between hematological inflammatory markers and BASDAI scores, despite observing some correlations between hematological markers and acute phase reactants.
These markers could be valuable assessment tools for indicating disease activity and monitoring patients with AS after initiating biological treatment.
中性粒细胞与淋巴细胞比值（NLR）、单核细胞与淋巴细胞比值（MLR）以及血小板与淋巴细胞比值（PLR）等血液学标志物是可靠的炎症指标。本研究旨在探讨这些标志物在评估初治生物制剂的强直性脊柱炎（AS）患者疾病活动度及治疗反应中的潜在作用。
我们将本研究设计为一项回顾性队列研究，数据来自单一中心。采用巴斯强直性脊柱炎疾病活动指数（BASDAI）和巴斯强直性脊柱炎功能指数（BASFI）评估AS患者的疾病活动度和功能状态。记录基线、第3、6和12个月的实验室检查结果。我们计算每次就诊时的血液学炎症标志物。还记录了平均血小板体积（MPV）和红细胞分布宽度（RDW）。
本研究纳入了54例初治生物制剂的AS患者。除RDW外，这些炎症标志物随时间下降。与基线值相比，第3、6和12个月时BASDAI、BASFI、CRP和ESR显著降低（所有p<0.001）。此外，与基线值相比，第3、6和12个月时NLR、PLR和MLR有统计学显著下降（所有p<0.001）。然而，比较第3、6和12个月的值时，未观察到统计学显著差异。尽管观察到血液学标志物与急性期反应物之间存在一些相关性，但我们也发现血液学炎症标志物与BASDAI评分之间无相关性。
这些标志物可能是用于指示疾病活动度及监测AS患者生物治疗后情况的有价值的评估工具。
